Cargando…

Vaccine confidence among those living with allergy during the COVID pandemic (ACCORD): A scoping review

BACKGROUND: Reports of allergic reactions to coronavirus disease 2019 (COVID-19) vaccines, coupled with an “infodemic” of misinformation, carry the potential to undermine confidence in the COVID-19 vaccines. However, no attempts have been made to comprehensively synthesize the literature on how alle...

Descripción completa

Detalles Bibliográficos
Autores principales: Batac, Ayel Luis R., Merrill, Kaitlyn A., Askin, Nicole, Golding, Michael A., Abrams, Elissa M., Bégin, Philippe, Ben-Shoshan, Moshe, Ladouceur, Erika, Roos, Leslie E., Protudjer, Vladan, Protudjer, Jennifer L.P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907785/
https://www.ncbi.nlm.nih.gov/pubmed/36785543
http://dx.doi.org/10.1016/j.jacig.2023.100079
Descripción
Sumario:BACKGROUND: Reports of allergic reactions to coronavirus disease 2019 (COVID-19) vaccines, coupled with an “infodemic” of misinformation, carry the potential to undermine confidence in the COVID-19 vaccines. However, no attempts have been made to comprehensively synthesize the literature on how allergic disease and fear of allergic reactions to the vaccines contribute to hesitancy. OBJECTIVES: Our aim was to review the academic and gray literature on COVID-19 vaccine hesitancy and allergic reactions. METHODS: We searched 4 databases (CINAHL, PsycINFO, MEDLINE, and Embase) using a search strategy developed by content and methodologic experts. No restrictions were applied regarding COVID-19 vaccine type, country of study, or patient age. Eligible articles were restricted to 10 languages. RESULTS: Of the 1385 unique records retrieved from our search, 60 articles (4.3%) were included. Allergic reactions to the COVID-19 vaccine were rare but slightly more common in individuals with a history of allergic disease. A fifth of the studies (13 of 60 [22%]) discussed vaccine hesitancy due to possibility of an allergic reaction. Additionally, the present review identified research on details of vaccine-related anaphylaxis (eg, a mean and median [excluding clinical trial data] of 12.4 and 5 cases per million doses, respectively) and allergic reactions (eg, a mean and median [excluding clinical trial data] of 489 and 528 cases per million doses, respectively). CONCLUSION: COVID-19 vaccine acceptance among individuals living with allergy and among those with no history of allergic disease may be affected by fear of an allergic reaction. Despite the low incidence of allergic reactions to the COVID-19 vaccine, fear of such reactions is one of the most commonly cited concerns reported in the literature.